β-Adrenoceptors in Cancer: Old Players and New Perspectives.

Distress, or negative stress, is known to considerably increase the incidence of several diseases, including cancer. There is indeed evidence from pre-clinical models that distress causes a catecholaminergic overdrive that, mainly through the activation of β-adrenoceptors (β-ARs), results in cancer cell growth and cancer progression. In addition, clinical studies have evidenced a role of negative stress in cancer progression. Moreover, plenty of data demonstrates that β-blockers have positive effects in reducing the pro-tumorigenic activity of catecholamines, correlating with better outcomes in some type of cancers as evidenced by several clinical trials. Among β-ARs, β2-AR seems to be the main β-AR subtype involved in tumor development and progression. However, there are data indicating that also β1-AR and β3-AR may be involved in certain tumors. In this chapter, we will review current knowledge on the role of the three β-AR isoforms in carcinogenesis as well as in cancer growth and progression, with particular emphasis on recent studies that are opening new avenues in the use of β-ARs as therapeutic targets in treating tumors. © 2023. The Author(s), under exclusive license to Springer Nature Switzerland AG.

Citation

Rosario Amato, Martina Lucchesi, Silvia Marracci, Luca Filippi, Massimo Dal Monte. β-Adrenoceptors in Cancer: Old Players and New Perspectives. Handbook of experimental pharmacology. 2024;285:665-688

Mesh Tags

Substances

PMID: 37982890

search → result